NextCure (NXTC)
Nasdaq Market Open
NextCure, Inc. is a clinical-stage biotechnology company developing targeted medicines for cancer and other serious diseases with high unmet need. Its work is centred on understanding how diseased tissue interacts with the immune system and on designing biologic therapies that can alter those interactions. The company is particularly focused on patients whose tumours fail to respond to existing treatments or progress after standard-of-care therapy.
NextCure’s pipeline includes NC410, a LAIR-2 fusion protein designed to disrupt immune-suppressive signals associated with collagen-rich tumour environments. The candidate is being studied in combination with pembrolizumab, with early clinical activity reported in areas including colorectal and ovarian cancers. The company is also advancing LNCB74, an antibody-drug conjugate directed at B7-H4, a cancer-associated target that is expressed in several tumour types and is viewed as clinically relevant for targeted oncology approaches.
Beyond these lead programmes, NextCure manages a broader portfolio that includes clinical assets such as NC525 and NC318, for which it is seeking partners. It also has earlier-stage programmes outside oncology, including NC605 for chronic bone diseases and NC181 for Alzheimer’s disease. As with many development-stage biopharmaceutical companies, its value is closely tied to clinical trial outcomes, regulatory progress, access to capital, and the ability to form collaborations that can support expensive late-stage development.
Last updated
- Market Cap
- 11.38M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- -3.79M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705
NextCure Provides Business Update
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
NextCure Provides Year-End Clinical Pipeline Updates
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 11.38M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -3.79M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.43
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.07
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -15.13
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -204.61%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -143.94%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.61
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 4.61
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 2.2
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 88.73K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 3.15
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -10.11M | -9.76M | -8.95M | -27.29M | -11.62M |
| EBITDA | -9.82M | -9.39M | -8.41M | -26.01M | -10.97M |
| Net income | -9.8M | -9.44M | -8.62M | -26.81M | -10.98M |
| Basic EPS | -1.87 | -0.81 | -3.22 | -11.29 | -4.7 |
| Diluted EPS | -1.87 | -0.81 | -3.22 | -11.29 | -4.7 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 37.98M | 50.18M | 39.61M | 47.69M | 67.14M |
| Total liabilities | 11.26M | 15.24M | 15.97M | 16.04M | 11.28M |
| Total equity | 26.72M | 34.94M | 23.65M | 29.65M | 55.86M |
| Cash & equivalents | 15.17M | 25.98M | 7.32M | 4.89M | 21.83M |
| Current assets | 31.74M | 43.75M | 32.64M | 40.02M | 58.9M |
| Current liabilities | 6.89M | 10.57M | 11M | 10.78M | 5.74M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -13.36M | -7.64M | -6.27M | -22.71M | -12.99M |
| Investing cash flow | 1.3M | 6M | 8.7M | 3.76M | 7.09M |
| Financing cash flow | 1.25M | 20.29M | 0 | 2.02M | — |
| Change in cash | -10.82M | 18.66M | 2.43M | -16.94M | -5.9M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — NextCure, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| edgar index | 10-Q — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — NextCure, Inc. | View Filing | |
| edgar index | DEF 14A — NextCure, Inc. | View Filing | |
| edgar index | DEFA14A — NextCure, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — NextCure, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| edgar index | 10-K — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G — NextCure, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — NextCure, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — NextCure, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing | |
| form 4 | Form 4 — Cobourn Steven P. | View Filing | |
| form 4 | Form 4 — Guha Udayan | View Filing | |
| form 4 | Form 4 — Mayer Timothy | View Filing | |
| form 4 | Form 4 — Kundu Sourav | View Filing | |
| form 4 | Form 4 — Richman Michael | View Filing | |
| form 4 | Form 4 — Shaw Kevin G. | View Filing | |
| edgar index | SCHEDULE 13G/A — NextCure, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — NextCure, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B1 — NextCure, Inc. | View Filing | |
| edgar index | EFFECT — NextCure, Inc. | View Filing | |
| edgar index | D — NextCure, Inc. | View Filing | |
| edgar index | CORRESP — NextCure, Inc. | View Filing | |
| edgar index | S-3 — NextCure, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — NextCure, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| edgar index | 10-Q — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — NextCure, Inc. | View Filing | |
| edgar index | 3/A — NextCure, Inc. | View Filing | |
| form 3 | Form 3 — Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | View Filing | |
| form 3 | Form 3 — Tang Renhong | View Filing | |
| form 3 | Form 3 — Ren Jinsheng | View Filing | |
| form 3 | Form 3 — Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | View Filing | |
| form 3 | Form 3 — Simcere Pharmaceutical Group Ltd | View Filing | |
| form 3 | Form 3 — Simcere Zaiming, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — NextCure, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — NextCure, Inc. | View Filing | |
| form 3 | Form 3 — Simcere Zaiming, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| edgar index | 10-Q — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B2 — NextCure, Inc. | View Filing | |
| edgar index | EFFECT — NextCure, Inc. | View Filing | |
| edgar index | CORRESP — NextCure, Inc. | View Filing | |
| edgar index | UPLOAD — NextCure, Inc. | View Filing | |
| edgar index | S-3 — NextCure, Inc. | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing | |
| edgar index | 4 — NextCure, Inc. | View Filing |